Which has stronger earnings and valuation, TLX or LBRX?

Telix Pharmaceuticals has higher revenue and earnings than LB Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 5.01 -$7.12M N/A N/A LB Pharmaceuticals N/A N/A -$25.20M -$1.73 N/A

Is TLX or LBRX more profitable?

Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A LB Pharmaceuticals N/A N/A N/A

Does the media refer more to TLX or LBRX?

In the previous week, LB Pharmaceuticals had 2 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 6 mentions for LB Pharmaceuticals and 4 mentions for Telix Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.80 beat Telix Pharmaceuticals' score of -0.32 indicating that LB Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral LB Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LBRX or BEAM?

In the previous week, Beam Therapeutics had 1 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 7 mentions for Beam Therapeutics and 6 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.80 beat Beam Therapeutics' score of 0.20 indicating that LB Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LBRX or RLAY more profitable?

LB Pharmaceuticals' return on equity of 0.00% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A N/A N/A Relay Therapeutics N/A -43.94% -40.11%

Does the media prefer LBRX or RLAY?

In the previous week, LB Pharmaceuticals had 3 more articles in the media than Relay Therapeutics. MarketBeat recorded 6 mentions for LB Pharmaceuticals and 3 mentions for Relay Therapeutics. LB Pharmaceuticals' average media sentiment score of 0.80 beat Relay Therapeutics' score of 0.24 indicating that LB Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer OGN or LBRX?

In the previous week, LB Pharmaceuticals had 4 more articles in the media than Organon & Co.. MarketBeat recorded 6 mentions for LB Pharmaceuticals and 2 mentions for Organon & Co.. LB Pharmaceuticals' average media sentiment score of 0.80 beat Organon & Co.'s score of 0.00 indicating that LB Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LB Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, LBRX or GPCR?

Structure Therapeutics is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LB Pharmaceuticals N/A N/A -$25.20M -$1.73 N/A Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A

Is LBRX or GPCR more profitable?

LB Pharmaceuticals' return on equity of 0.00% beat Structure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A N/A N/A Structure Therapeutics N/A -24.91% -23.67%

Does the media prefer LBRX or GPCR?

In the previous week, LB Pharmaceuticals had 5 more articles in the media than Structure Therapeutics. MarketBeat recorded 6 mentions for LB Pharmaceuticals and 1 mentions for Structure Therapeutics. LB Pharmaceuticals' average media sentiment score of 0.80 beat Structure Therapeutics' score of 0.00 indicating that LB Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

LB Pharmaceuticals (LBRX) Competitors

$33.43 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$33.38 -0.05 (-0.13%)

As of 07/2/2026 07:18 PM Eastern

Compare

LBRX vs. TLX, BEAM, RLAY, OGN, and GPCR

Should you buy LB Pharmaceuticals stock or one of its competitors? MarketBeat compares LB Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LB Pharmaceuticals include Telix Pharmaceuticals (TLX), Beam Therapeutics (BEAM), Relay Therapeutics (RLAY), Organon & Co. (OGN), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

How does LB Pharmaceuticals compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and LB Pharmaceuticals (NASDAQ:LBRX) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

In the previous week, LB Pharmaceuticals had 2 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 6 mentions for LB Pharmaceuticals and 4 mentions for Telix Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.80 beat Telix Pharmaceuticals' score of -0.32 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
LB Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals presently has a consensus price target of $21.13, suggesting a potential upside of 77.97%. LB Pharmaceuticals has a consensus price target of $38.40, suggesting a potential upside of 14.87%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Telix Pharmaceuticals is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Telix Pharmaceuticals has higher revenue and earnings than LB Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	5.01	-$7.12M	N/A	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
LB Pharmaceuticals	N/A	N/A	N/A

Summary

Telix Pharmaceuticals beats LB Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Beam Therapeutics?

LB Pharmaceuticals (NASDAQ:LBRX) and Beam Therapeutics (NASDAQ:BEAM) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

LB Pharmaceuticals has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. LB Pharmaceuticals' return on equity of 0.00% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	N/A	N/A
Beam Therapeutics	-39.66%	-29.00%	-22.61%

99.7% of Beam Therapeutics shares are held by institutional investors. 5.8% of LB Pharmaceuticals shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

LB Pharmaceuticals currently has a consensus target price of $38.40, suggesting a potential upside of 14.87%. Beam Therapeutics has a consensus target price of $46.83, suggesting a potential upside of 34.62%. Given Beam Therapeutics' higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Beam Therapeutics had 1 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 7 mentions for Beam Therapeutics and 6 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.80 beat Beam Therapeutics' score of 0.20 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LB Pharmaceuticals has higher earnings, but lower revenue than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Beam Therapeutics	$139.74M	25.61	-$79.99M	-$0.68	N/A

Summary

LB Pharmaceuticals beats Beam Therapeutics on 8 of the 14 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Relay Therapeutics?

LB Pharmaceuticals (NASDAQ:LBRX) and Relay Therapeutics (NASDAQ:RLAY) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

LB Pharmaceuticals currently has a consensus price target of $38.40, suggesting a potential upside of 14.87%. Relay Therapeutics has a consensus price target of $23.30, suggesting a potential upside of 24.93%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

97.0% of Relay Therapeutics shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

LB Pharmaceuticals has higher earnings, but lower revenue than Relay Therapeutics. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Relay Therapeutics	$15.35M	232.78	-$276.48M	-$1.57	N/A

LB Pharmaceuticals' return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	N/A	N/A
Relay Therapeutics	N/A	-43.94%	-40.11%

In the previous week, LB Pharmaceuticals had 3 more articles in the media than Relay Therapeutics. MarketBeat recorded 6 mentions for LB Pharmaceuticals and 3 mentions for Relay Therapeutics. LB Pharmaceuticals' average media sentiment score of 0.80 beat Relay Therapeutics' score of 0.24 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Relay Therapeutics beats LB Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and LB Pharmaceuticals (NASDAQ:LBRX) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Organon & Co. presently has a consensus target price of $11.40, indicating a potential downside of 15.96%. LB Pharmaceuticals has a consensus target price of $38.40, indicating a potential upside of 14.87%. Given LB Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe LB Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Organon & Co. has a net margin of 3.99% compared to LB Pharmaceuticals' net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat LB Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
LB Pharmaceuticals	N/A	N/A	N/A

Organon & Co. has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.16B	0.58	$187M	$0.93	14.59
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A

In the previous week, LB Pharmaceuticals had 4 more articles in the media than Organon & Co.. MarketBeat recorded 6 mentions for LB Pharmaceuticals and 2 mentions for Organon & Co.. LB Pharmaceuticals' average media sentiment score of 0.80 beat Organon & Co.'s score of 0.00 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LB Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.4% of Organon & Co. shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by company insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Organon & Co. beats LB Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Structure Therapeutics?

LB Pharmaceuticals (NASDAQ:LBRX) and Structure Therapeutics (NASDAQ:GPCR) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Structure Therapeutics is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

LB Pharmaceuticals' return on equity of 0.00% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	N/A	N/A
Structure Therapeutics	N/A	-24.91%	-23.67%

91.8% of Structure Therapeutics shares are held by institutional investors. 5.8% of LB Pharmaceuticals shares are held by insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, LB Pharmaceuticals had 5 more articles in the media than Structure Therapeutics. MarketBeat recorded 6 mentions for LB Pharmaceuticals and 1 mentions for Structure Therapeutics. LB Pharmaceuticals' average media sentiment score of 0.80 beat Structure Therapeutics' score of 0.00 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LB Pharmaceuticals presently has a consensus price target of $38.40, indicating a potential upside of 14.87%. Structure Therapeutics has a consensus price target of $110.55, indicating a potential upside of 106.82%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Summary

LB Pharmaceuticals beats Structure Therapeutics on 7 of the 13 factors compared between the two stocks.

Get LB Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LBRX vs. The Competition

Export

Metric	LB Pharmaceuticals	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$958.67M	$3.13B	$4.50B	$12.59B
Dividend Yield	N/A	15.23%	17.12%	6.63%
P/E Ratio	-19.32	13.55	23.83	24.71
Price / Sales	N/A	2,848.27	156.04	96.70
Price / Cash	N/A	26.14	35.72	58.15
Price / Book	2.81	5.15	13.25	6.45
Net Income	-$25.20M	-$34.63M	$113.80M	$336.71M
7 Day Performance	4.73%	0.95%	0.90%	1.37%
1 Month Performance	19.61%	-0.80%	-1.44%	1.67%
1 Year Performance	N/A	12.19%	10.46%	24.05%

LB Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LBRX LB Pharmaceuticals	1.3754 of 5 stars	$33.43 flat	$38.40 +14.9%	N/A	$958.67M	N/A	N/A	16
TLX Telix Pharmaceuticals	4.5098 of 5 stars	$11.30 +6.0%	$21.13 +86.9%	-28.1%	$3.62B	$803.79M	N/A	1,184	Gap Up
BEAM Beam Therapeutics	2.155 of 5 stars	$34.95 +0.4%	$46.83 +34.0%	+75.0%	$3.58B	$139.74M	N/A	510
RLAY Relay Therapeutics	2.8582 of 5 stars	$19.74 +6.4%	$23.30 +18.0%	+418.1%	$3.56B	$15.35M	N/A	330	Insider Trade
OGN Organon & Co.	1.7083 of 5 stars	$13.54 +0.3%	$11.40 -15.8%	+33.5%	$3.55B	$6.22B	14.55	10,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LBRX) was last updated on 7/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LB Pharmaceuticals (LBRX) Competitors

LBRX vs. TLX, BEAM, RLAY, OGN, and GPCR

How does LB Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

How does LB Pharmaceuticals compare to Beam Therapeutics?

Summary

How does LB Pharmaceuticals compare to Relay Therapeutics?

Summary

How does LB Pharmaceuticals compare to Organon & Co.?

Summary

How does LB Pharmaceuticals compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LBRX vs. The Competition

LB Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LB Pharmaceuticals (LBRX) Competitors

LBRX vs. TLX, BEAM, RLAY, OGN, and GPCR

How does LB Pharmaceuticals compare to Telix Pharmaceuticals?

Does the media refer more to TLX or LBRX?

Do analysts rate TLX or LBRX?

Which has stronger earnings and valuation, TLX or LBRX?

Is TLX or LBRX more profitable?

Summary

How does LB Pharmaceuticals compare to Beam Therapeutics?

Is LBRX or BEAM more profitable?

Do institutionals & insiders have more ownership in LBRX or BEAM?

Do analysts rate LBRX or BEAM?

Does the media refer more to LBRX or BEAM?

Which has better earnings & valuation, LBRX or BEAM?

Summary

How does LB Pharmaceuticals compare to Relay Therapeutics?

Do analysts rate LBRX or RLAY?

Do insiders & institutionals hold more shares of LBRX or RLAY?

Which has stronger earnings and valuation, LBRX or RLAY?

Is LBRX or RLAY more profitable?

Does the media prefer LBRX or RLAY?

Summary

How does LB Pharmaceuticals compare to Organon & Co.?

Do analysts recommend OGN or LBRX?

Is OGN or LBRX more profitable?

Which has stronger valuation & earnings, OGN or LBRX?

Does the media prefer OGN or LBRX?

Do institutionals & insiders believe in OGN or LBRX?

Summary

How does LB Pharmaceuticals compare to Structure Therapeutics?

Which has higher earnings & valuation, LBRX or GPCR?

Is LBRX or GPCR more profitable?

Do insiders & institutionals believe in LBRX or GPCR?

Does the media prefer LBRX or GPCR?

Do analysts prefer LBRX or GPCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LBRX vs. The Competition

LB Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools